


# LUNG CANCER

## Personalized TumorGraft™ case study: 50-year-old male diagnosed with stage IV non small cell lung cancer who had 2 prior regimens<sup>1</sup>

First line of a Taxol and Cisplatin therapy, second-line treatment with Alimta and Avastin

### PERSONALIZED TUMORGRAFT™ RESPONSE TO DRUG TESTING



- Physician elected to treat patient with third-line treatment (Sorafenib, Bevacizumab and Irinotecan) based on Personalized TumorGraft™ results
- Patient’s tumor regressed (partial response) for 9 months
- Triple therapy was then discontinued due to side effects
- Sorafenib alone was continued and delivered another 6 months of remission

### Case study conclusion

- Patient responded to one course of Champions-guided treatment
- Patient lived 15 months on late-line therapy

<sup>1</sup>Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther June 2011.